secwatch.observer — SEC 8-K summary
======================================

Issuer:     TriSalus Life Sciences, Inc. (TLSI)
CIK:        0001826667
Form:       8-K
Filed at:   2026-04-07T23:59:59+00:00
Accession:  0001628280-26-023991
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TriSalus appoints Dr. Richard Marshall as CMO, effective June 29, 2026
----------------------------------------------------------------------

- Annual base salary of $525,000; sign-on bonus of $250,000.
- Eligible for annual bonus up to 50% of base salary based on board-determined goals.
- Board will recommend granting 120,000 stock options and 60,000 restricted stock units.
- Marshall, previously Medical Director since Jan 2025, will lead medical strategy and clinical development.
- Appointment strengthens leadership as TriSalus advances its PEDD platform for solid tumors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826667/000162828026023991/0001628280-26-023991-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826667/000162828026023991/tlsi-20260401.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-023991

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer